Kalbe Farma Finance Director Vidjongius on Thursday said net sales rose 5.8 percent to Rp7.962 trillion from Rp7.272 trillion and gross profit rose 9.0 percent to Rp1.404 trillion from Rp1.288 trillion in same period last year.
This was mostly driven by increases in income from operations and other income, and lower minority interests in net earnings of subsidiaries. Earnings per share increased by 18.1 percent, from Rp96 per share to Rp114 per share.
"The global financial crisis affected the Indonesian rupiah`s exchange rate in the third quarter. But it was not significant because we had enough raw materials, finished goods as well as US dollar reserve funds, and were supported by diligent production cost control," he said.
KLBF is one of the largest publicly-listed pharmaceutical companies in Southeast Asia.(*)
Editor: Heru Purwanto
Copyright © ANTARA 2011
